Development of new tharapy and search for new cell death mechanism in hematologic malignancies

我们已经做了以下三个项目，以开发新的治疗化疗无效的血液系统恶性肿瘤。(1)在体内寻找难治性白血病新的细胞死亡机制（2）寻找难治性白血病新的预后因素（3）分析AML微小残留病（MRD）中细胞的功能。(1)我们检测了移植了Ph 1 ALL白血病细胞的NOG小鼠经达沙替尼治疗后骨髓、肝脏、脾脏和颅脊髓系统中的自噬细胞。(2)我们分析了AML-05样品中的KIT突变。KIT突变阳性患者的无事件生存率较差，复发率较高。(3)我们仅在唐氏综合征患者中检测到CD 34 + CD 33+前体细胞中的CD 56表达，而在非唐氏综合征患者中未检测到。我们必须仔细分析MRD检测，特别是唐氏综合征患者。

We have done the following three projects to develop new therapies for chemo-resisitant hematologic malignancies. (1) To search new cell death mechanism of refractory leukemia in vivo (2) To search new prognostic factors in refractory leukemia (3) Analyze function of cells in minimal residual disease (MRD) of AML. (1) We detected autophagic cells in bone marrow, liver, spleen and craniospinal system of NOG mouse transplanted Ph1 ALL leukemic cells after treatment of dasatinib. (2) We analysed KIT mutations in AML-05 samples. Event free survivals are poor and relapse rates are high in KIT mutation positive patients. (3) We detected CD56 expression in CD34+CD33+ precursor cells only in Down syndrome patients and not in non-Down syndrome patients. We have to be carefully analyse MRD detection especially in Down syndrome patients.